
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4330633/publications.pdf Version: 2024-02-01



DOMINIQUE FARCE

#	Article	IF	CITATIONS
1	Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. Rheumatology, 2023, 62, SI32-SI42.	1.9	4
2	Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology, 2022, 61, 1936-1947.	1.9	15
3	Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study. Journal of Thrombosis and Thrombolysis, 2022, 53, 417-424.	2.1	4
4	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	2.5	3
5	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica, 2021, 106, 375-383.	3.5	57
6	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Healthâ€Related Quality of Life. Arthritis and Rheumatology, 2021, 73, 305-314.	5.6	10
7	Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmunity Reviews, 2021, 20, 102755.	5.8	28
8	Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation. Journal of Neurology, 2021, 268, 1536-1539.	3.6	8
9	Autologous stem cell transplantation in scleroderma. Presse Medicale, 2021, 50, 104065.	1.9	10
10	New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplantation, 2021, 56, 1509-1517.	2.4	14
11	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 2021, 56, 1493-1508.	2.4	27
12	Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transplantation, 2021, 56, 2259-2267.	2.4	7
13	Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. Diagnostics, 2021, 11, 1064.	2.6	6
14	Patient education program at the forefront of cancer-associated thrombosis care. JMV-Journal De Medecine Vasculaire, 2021, 46, 215-223.	0.2	2
15	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 441-451.	2.4	22
16	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	2.4	128
17	Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transplantation, 2020, 55, 1512-1515.	2.4	12
18	Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1473-1475.	2.4	9

#	Article	IF	CITATIONS
19	Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology, 2020, 158, 1346-1358.e4.	1.3	48
20	How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units. JMV-Journal De Medecine Vasculaire, 2020, 45, 334-343.	0.2	8
21	What is the current state of thrombosis treatment and prevention in cancer patients?. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S1-6S2.	0.2	0
22	How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S24-6S30.	0.2	1
23	Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S31-6S38.	0.2	8
24	Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry. TH Open, 2020, 04, e236-e244.	1.4	6
25	Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. JMV-Journal De Medecine Vasculaire, 2020, 45, 268-274.	0.2	47
26	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). JMV-Journal De Medecine Vasculaire, 2020, 45, 28-40.	0.2	3
27	Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. F1000Research, 2019, 8, 974.	1.6	11
28	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Frontiers in Immunology, 2019, 10, 1570.	4.8	48
29	Women, thrombosis, and cancer. Thrombosis Research, 2019, 181, S47-S53.	1.7	7
30	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
31	Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clinical Rheumatology, 2019, 38, 1501-1511.	2.2	7
32	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow	2.4	25
33	Transplantation, 2019, 54, 933-942. Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. Stem Cells International, 2019, 2019, 1-7.	2.5	19
34	Lysyl oxidase—a possible role in systemic sclerosis–associated pulmonary hypertension: a multicentre study. Rheumatology, 2019, 58, 1547-1555.	1.9	15
35	2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply. Lancet Oncology, The, 2019, 20, e656.	10.7	25
36	Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. Cancers, 2019, 11, 71.	3.7	30

#	Article	IF	CITATIONS
37	Autologous HSCT is efficacious, but can we make it safer?. Nature Reviews Rheumatology, 2018, 14, 189-191.	8.0	26
38	A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports, 2018, 10, 933-941.	4.8	79
39	Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. Thrombosis and Haemostasis, 2018, 118, 1119-1122.	3.4	4
40	Left Ventricle Replacement Fibrosis Detected by CMR Associated With Cardiovascular Events in Systemic Sclerosis Patients. Journal of the American College of Cardiology, 2018, 71, 703-705.	2.8	19
41	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.9	50
42	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. European Heart Journal, 2018, 39, 4208-4218.	2.2	267
43	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis, 2018, 12, 1097-1103.	1.3	29
44	Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. Journal of Rheumatology, 2018, 45, 1273-1280.	2.0	17
45	Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. Journal of Autoimmunity, 2018, 92, 35-46.	6.5	51
46	Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Oncotarget, 2018, 9, 26990-26999.	1.8	13
47	Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP). Blood, 2018, 132, 3431-3431.	1.4	0
48	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 68-75.	0.8	3
49	Women, thrombosis, and cancer: A gender-specific analysis. Thrombosis Research, 2017, 151, S21-S29.	1.7	11
50	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	9.0	199
51	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
52	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplantation, 2017, 52, 1495-1503.	2.4	88
53	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon, 2017, 3, e00229.	3.2	19
54	Incidence, risk factors, and outcomes of central venous catheterâ€related thromboembolism in breast cancer patients: the <scp>CAVECCAS</scp> study. Cancer Medicine, 2017, 6, 2732-2744.	2.8	30

DOMINIQUE FARGE

#	Article	IF	CITATIONS
55	Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplantation, 2017, 52, 1674-1677.	2.4	22
56	Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. Journal of Hematology and Oncology, 2017, 10, 21.	17.0	51
57	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	5.2	151
58	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 114-121.	0.8	1
59	Clinical practice guidelines for prophylaxis of venous thomboembolism in cancer patients. Thrombosis and Haemostasis, 2016, 116, 618-625.	3.4	18
60	Right heart thrombi in pulmonary embolism. European Respiratory Journal, 2016, 48, 1377-1385.	6.7	58
61	Prophylaxis of venous thromboembolism in cancer patients. Expert Review of Hematology, 2016, 9, 535-539.	2.2	7
62	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2016, 17, e452-e466.	10.7	315
63	FRI0244â€Lysyl Oxidase as A Biomarker in Systemic Sclerosis– A Multicenter Study. Annals of the Rheumatic Diseases, 2016, 75, 522.1-522.	0.9	0
64	Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. Current Research in Translational Medicine, 2016, 64, 107-113.	1.8	32
65	Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice. Current Research in Translational Medicine, 2016, 64, 71-82.	1.8	32
66	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (United States), 2015, 94, e1235.	1.0	43
67	PTU-083ÂSubstantial histological improvement following haemopoetic stem cell transplantation: Abstract PTU-083 Table 1. Gut, 2015, 64, A97.1-A97.	12.1	1
68	Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Research and Therapy, 2015, 17, 301.	3.5	67
69	Transforming growth factor-β increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 196.	3.5	22
70	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2015, 84, 981-988.	1.1	201
71	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	7.4	136
72	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	3.0	56

#	Article	IF	CITATIONS
73	Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplantation, 2015, 50, 216-220.	2.4	38
74	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplantation, 2015, 50, 173-180.	2.4	71
75	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	7.4	566
76	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1803.	7.4	3
77	Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study. Journal Des Maladies Vasculaires, 2014, 39, 161-168.	0.6	46
78	Therapy for Cancer-Related Thromboembolism. Seminars in Oncology, 2014, 41, 319-338.	2.2	26
79	Implementing Thrombosis Guidelines in Cancer Patients: A Review. Rambam Maimonides Medical Journal, 2014, 5, e0041.	1.0	8
80	Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?. Blood, 2014, 124, 2517-2517.	1.4	0
81	New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2013, 121, 1059-1064.	1.4	69
82	Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus, 2013, 22, 245-253.	1.6	80
83	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet, The, 2013, 381, 1116-1124.	13.7	129
84	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2013, 11, 56-70.	3.8	469
85	LB0002â€The astis trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. Annals of the Rheumatic Diseases, 2013, 71, 151-151.	0.9	16
86	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	2.4	256
87	International guidelines for antithrombotics in cancer patients Journal of Clinical Oncology, 2012, 30, e13062-e13062.	1.6	0
88	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Annals of the Rheumatic Diseases, 2011, 70, 1788-1792.	0.9	107
89	Autologous HSCT in systemic sclerosis: a step forward. Lancet, The, 2011, 378, 460-462.	13.7	6
90	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood, 2011, 118, 1693-1698.	1.4	140

#	Article	IF	CITATIONS
91	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 2071-2074.	0.9	58
92	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 2010, 95, 284-292.	3.5	321
93	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 218-221.	0.9	214
94	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. Blood, 2010, 116, 2322-2322.	1.4	0
95	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. Journal of Rheumatology, 2009, 36, 1460-1463.	2.0	38
96	Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplantation, 2009, 44, 27-33.	2.4	79
97	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Annals of the Rheumatic Diseases, 2008, 67, 98-104.	0.9	149
98	Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Blood, 2008, 112, 164-164.	1.4	3
99	Skin involvement in scleroderma–where histological and clinical scores meet. Rheumatology, 2007, 46, 833-841.	1.9	123
100	Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clinical Rheumatology, 2005, 24, 3-10.	2.2	71
101	Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer. Archives of Internal Medicine, 2002, 162, 1729.	3.8	727
102	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase l–II study. British Journal of Haematology, 2002, 119, 726-739.	2.5	119
103	Simultaneous progressive multifocal leukoencephalopathy, Epstein-Barr virus (EBV) latent infection and cerebral parenchymal infiltration during chronic lymphocytic leukemia. Leukemia, 1994, 8, 318-21.	7.2	11